Open AccessIntegrated approach in the treatment of metabolic syndrome
Author(s) -
Vera A. Uchamprina,
Т. И. Романцова,
Марина Федоровна Калашникова
Publication year - 2014
Publication title -
ožirenie i metabolizm
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.154
H-Index - 5
eISSN - 2306-5524
pISSN - 2071-8713
DOI - 10.14341/omet2014132-37
Subject(s) - medicine , pharmacotherapy , orlistat , metformin , insulin resistance , metabolic syndrome , depression (economics) , obesity , blood pressure , quality of life (healthcare) , combination therapy , waist , lipid profile , beck depression inventory , weight loss , insulin , cholesterol , psychiatry , nursing , economics , macroeconomics , anxiety
The Goal of this study was to investigate the efficacy of the integrated approach for the treatment of metabolic syndrome (MS) aiming to correct all of its components versus standard therapy using clinical outcomes (BMI, waist circumference, blood pressure, lipid levels), assessment of psychological status (Beck Depression Inventory), and quality of life (SF-36). Methods: A total of 60 patients with MS were included in the study. The study group (30 subjects mean age 41.0±11 years, women - 23 (76.7%), men - 7 (23.3%)) received the complex therapy of MS - pharmacotherapy of obesity (orlistat) and insulin resistance (metformin), lipid-lowering therapy (statins or fibrates), antihypertensive therapy. Control group (30 patients mean age 43.4±9.5 years, women - 26 (86.7%), men - 4 (13.3%)) was treated with statins or fibrates and received antihypertensive therapy when needed. At the inclusion in the study and after 6 months of therapy all patients underwent clinical and laboratory investigation, assessment of depression and quality of life. Results: We found a more significant reduction of all clinical outcomes (body weight, blood pressure, improvement in glucose and lipid metabolism), a significant decrease in the prevalence and severity of the depression, and an improvement in the quality of life in patients of study group compared with standard therapy. Conclusion: Complex treatment of the MS, including pharmacotherapy of obesity (orlistat, Xenical) and insulin resistance (metformin, Glucophage) is characterized by a greater clinical efficacy compared with standard therapy.